Trial Profile

Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pidnarulex (Primary) ; Talazoparib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms REPAIR

Most Recent Events

31 Oct 2022 According to a Senhwa Biosciences media release, first patient has been dosed in this study.
26 Oct 2022 Status changed from not yet recruiting to recruiting.
23 Jun 2022 New Source Identified and Integrated (ClinicalTrials.gov: US National Institutes of Health NCT05425862)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com